HVTN Activities at HIVR4P

HVTN will be attending the HIV Research for Prevention Conference in Madrid, Spain, from October 21–25, 2018. Below, find a list of HVTN’s activities at HIVR4P, including satellite sessions and abstract presentations. To view the online R4P program, click here

  • For a PDF of a dedicated program detailing all HVTN-related HIVR4P activities, click here (pdf).
  • For more information, please contact Aziel Gangerdine at agangerd@fredhutch.org or (206) 667-7875.

Satellite Sessions | Latebreaker Abstract Presentations | General Abstract Presentations | Plenary Speakers | Symposiums

Satellite Sessions

State of the Art of HIV bNAbs for Prevention of HIV Infection
October 21, 2018, 4 p.m.–6 p.m.
Larry Corey, Fred Hutchinson Cancer Research Center
Myron Cohen, University of North Carolina
Hosted by HVTN and HPTN

A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HIV Vaccine Trials Network
October 22, 2018, 8:30 a.m. –11:30 a.m.
James Kublin, Fred Hutchinson Cancer Research Center
Ashley Clayton, Fred Hutchinson Cancer Research Center


Latebreaker Abstract Presentations

Human Gut Microbiota are Associated with HIV-reactive Immunoglobulin at Baseline and Following HIV Vaccination
Presenting Author: Jim Kublin

Immune Responses to PENNVAX-GP® HIV DNA Vaccine plus IL-12 are Equivalent or Superior when Delivered by Intradermal vs. Intramuscular Electroporation
Presenting Author: Sri Edupuganti

Increase in Env-Specific Binding Antibody and CD4+ T Cell-Responses After Month 30 Boost of gp120/MF59 Delivered Alone or with ALVAC-HIV
Presenting Author: Kristen Cohen

Co-administration of 3 doses of DNA/Protein Improves Antibody Responses to a Prime-Boost Approach, but Needle-Free Injection of DNA Shows No Benefit
Presenting Author: Mina Hosseinipour

HVTN 114: A Phase 1 Trial to Evaluate Late Boosts with AIDSVAX B/E of Participants Previously Vaccinated with MVA/HIV62B in DNA/MVA or MVA Regimens
Presenting Author: Paul Goepfert

Rectal Biopsies from Men and Women Infused Intravenously with VRC01 mAb Show Partial Protection that Wanes Over Time in Ex Vivo HIV-1 Challenges
Presenting Author: Maria Lemos

Tetravalent Janssen Mosaic Ad26/Protein HIV vaccine shows increased Clade C Env-specific CD4+ T-Cell and Antibody Responses versus trivalent vaccine
Presenting Author: Georgia Tomaras

Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens
Presenting Author: Daniel Stieh

DNA-prime Induces Higher Magnitude Humoral Responses than ALVAC-prime in HIV Vaccine Regimens with the Same Protein Boost
Presenting Author: Zoe Moodie

Antibody Mediated Prevention: Proof-of-Concept, Randomized, Blinded, Placebo-Controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1
Presenting Author: Sri Edupuganti

Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People
Presenting Author: Phil Andrew

A meta-analysis to evaluate the relationship between serum antibody neutralizing titer and protection against SHIV challenge in nonhuman primates for 16 broadly neutralizing HIV antibodies
Presenting Author: Yunda Huang


General Abstract Presentations

Systems Analysis of the Innate and Adaptive Immune Responses to the RV144 ALVAC HIV Vaccine in a South African HIV Uninfected Cohort
Presenting Author: Lamar Fleming

Expansion of VH1-2*02 Env-Specific B Cells in a Non-Neutralizing HIV-1 Env Vaccine Regimen
Presenting Author: Lamar Fleming

Induction and Relationship of HIV Envelope-Specific B Cells in the Peripheral Blood and Bone Marrow Following Vaccination in Humans
Presenting Author: James Kobie

Increased Breadth of T-Cell Responses After Mosaic HIV Vaccination in Humans
Presenting Author: Nicole Frahm

Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial
Presenting Author: Greg Wilson

Vaccine-Encoded Adapted Epitopes Infrequently Induce CD8 T Cell Responses
Presenting Author: Sushma Boppana

V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa
Presenting Author: Xiaoying Shen

Impact of Vaccine Regimen on Vaccine Induced Antibody Durability
Presenting Author: Kelly Seaton

Standardized Metrics Can Reveal Region-Specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials
Presenting Author: Gail Broder 

Prediction of VRC01 Neutralization Sensitivity by HIV-1 gp160 Sequence Features Germline-Targeting and Reverse Engineering to Elicit CH235.12 Lineage BNAbs
Presenting Author: Shay Behrens


Plenary Speakers

Opening Plenary: Planning for Success (and the Challenges Ahead)
Monday, October 22, 16:00–18:00
Linda-Gail Bekker, Desmond Tutu HIV Center
HIV Vaccines: Where Are We and What Next? [PL01.01]

Closing Plenary: Putting It Together: Strategies to End the Epidemic
Thursday, October 25, 15:00–16:30
John Mascola, Vaccine Research Center, NIAID, NIH
A Path Forward for HIV Vaccines [PL04.04]



Symposium 1
We Want bnAbs: Passively Infused and Induced by Vaccines

Tuesday, October 23, 15:00–16:30
Lynn Morris, National Institute for Communicable Diseases of the NHLS
Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It’s Working? [SY01.02]

Symposium 5
Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination

Wednesday, October 24, 15:00–16:30
R. Keith Reeves, Beth Israel Harvard
The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface [SY05.04]

Symposium 8
Translating Vaccine Concepts to the Clinic: What We Need to Know

Thursday, October 25, 13:00–14:30
Guido Ferrari, Duke University Medical Center
Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses [SY08.02]